文献速递创伤与烧伤儿科与产科急症复苏、休克与脓毒症

氨甲环酸用于需大量输血的儿科战伤患者与死亡率

Tranexamic acid in pediatric combat trauma requiring massive transfusions and mortality.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论儿科战伤需大量输血者接受氨甲环酸后院内死亡率8.5% vs 18.3%,但差异未达统计学显著,logistic回归OR 0.35(95%CI 0.123-0.995,P=0.0488)。

该回顾性队列研究查询国防部创伤登记库,纳入伊拉克和阿富汗战伤、年龄小于18岁、伤后24小时内接受40 mL/kg或以上血制品的患儿,排除烧伤和致命性颅脑创伤。接受氨甲环酸者院内死亡率8.5%,未接受者为18.3%,差异未达统计学显著(P=0.055);logistic回归显示氨甲环酸显著降低死亡比值比(OR 0.35,95%CI 0.123-0.995,P=0.0488)。两组无住院天数、无呼吸机天数、无ICU天数相似,接受氨甲环酸者24小时血制品用量更高(100 mL/kg vs 75 mL/kg)。作者认为氨甲环酸可能为需大量输血的儿科战伤患者带来生存获益。

要点

  • 儿科战伤需大量输血(24小时内≥40 mL/kg血制品)者,接受氨甲环酸院内死亡率8.5% vs 未接受者18.3%,差异未达统计学显著(P=0.055)。
  • logistic回归显示氨甲环酸显著降低死亡比值比:OR 0.35(95%CI 0.123-0.995,P=0.0488)。
  • 接受氨甲环酸者24小时血制品用量更高:100 mL/kg vs 75 mL/kg,两组无住院天数(19 vs 20)、无呼吸机天数(27 vs 27)、无ICU天数(25 vs 24)相似。
  • 该研究为回顾性队列(证据等级Level IV),作者认为氨甲环酸的死亡率获益与成人研究及另一儿科研究相似。

适用人群与场景

  • 伊拉克和阿富汗战伤、年龄小于18岁、伤后24小时内接受40 mL/kg或以上血制品的儿科患者。
  • 排除烧伤和致命性颅脑创伤。

研究设计与关键结果

  • 研究类型为回顾性队列,数据来自国防部创伤登记库,纳入伊拉克和阿富汗战伤、年龄小于18岁、伤后24小时内接受40 mL/kg或以上血制品的患者,排除烧伤和致命性颅脑创伤。
  • 主要终点为院内死亡率:接受氨甲环酸者8.5% vs 未接受者18.3%,差异未达统计学显著(P=0.055)。
  • logistic回归显示氨甲环酸显著降低死亡比值比:OR 0.35(95%CI 0.123-0.995,P=0.0488)。
  • 次要终点:无住院天数19 vs 20、无呼吸机天数27 vs 27、无ICU天数25 vs 24,两组相似。
  • 接受氨甲环酸者24小时血制品用量更高:100 mL/kg vs 75 mL/kg。

证据类型、等级与局限

  • 证据类型:回顾性队列,证据等级Level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,氨甲环酸在需大量输血的儿科战伤患者中使院内死亡率有改善趋势(P=0.055),该获益与成人研究及另一儿科研究相似。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Tranexamic acid (TXA) has been demonstrated to decrease mortality in adult trauma, particularly in those with massive transfusions needs sustained in combat injury. Limited data are available for the efficacy of TXA in pediatric trauma patients outside of a single combat support hospital in Afghanistan.

METHODS: The Department of Defense Trauma Registry was queried for trauma patients younger than 18 years from Iraq and Afghanistan requiring 40 mL/kg or greater of blood product within 24 hours of injury. Burns and fatal head traumas were excluded. Primary outcome was in-hospital mortality. Secondary outcomes were hospital, ventilator, and intensive care unit-free days, as well as total blood product volume.

RESULTS: Among those pediatric patients receiving massive transfusions, those who received TXA were less likely to die in hospital (8.5% vs. 18.3%). Patients who received TXA and those who did not have similar hospital-free days (19 vs. 20), ventilator-free days (27 vs. 27), and intensive care unit-free days (25 vs. 24). Those who received TXA had higher 24-hour blood product administration (100 mL/kg vs. 75 mL/kg). None of our results rose to the level of statistical significance. The TXA administration significantly reduced odds of death on logistic regression (odds ratio, 0.35; 95% confidence interval, 0.123-0.995; p = 0.0488).

CONCLUSION: Use of TXA in pediatric patients with combat trauma requiring massive transfusions trended toward a significant improvement in in-hospital mortality (p = 0.055). This mortality benefit is similar to that seen in adult studies and a less well characterized cohort in another pediatric study suggesting TXA administration confers mortality benefit in massively transfused pediatric combat trauma victims.

LEVEL OF EVIDENCE: Evidence (retrospective cohort), Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Hamele M, Aden JK, Borgman MA, et al. Tranexamic acid in pediatric combat trauma requiring massive transfusions and mortality. J Trauma Acute Care Surg. 2020. PMID: 32265388. doi:10.1097/TA.0000000000002701

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。